Category: Markets
Published: 2026-08-17T16:42:50.000Z
Lexaria Bioscience (LEXX) has successfully regained compliance with Nasdaq's $1.00 bid-price requirement and will maintain its listing on The Nasdaq Capital Market. Nasdaq confirmed that the company met Listing Rule 5550(a)(2) on August 17, 2026, leading to the cancellation of the previously scheduled Nasdaq hearing. Lexaria Bioscience's common stock will continue to trade on the Nasdaq Capital Market.
News summary curated and translated by CausifyMarket. Always consult original sources before making any financial decision.